Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/01/2016 02/02/2016 02/03/2016 02/04/2016 02/05/2016 Date
0.84(c) 0.8198(c) 0.8401(c) 0.88(c) 0.859(c) Last
201 043 193 075 43 667 59 169 73 668 Volume
-4.55% -2.40% +2.48% +4.75% -2.39% Change
More quotes
Financials ($)
Sales 2016 0,20 M
EBIT 2016 -27,2 M
Net income 2016 -26,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 1,40 M
EBIT 2017 -30,1 M
Net income 2017 -28,6 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 334x
Capi. / Sales 2017 47,5x
Capitalization 66,6 M
More Financials
Company
Pluristem Therapeutics, Inc. engages in the development of standardized cell therapy products for the treatment of life threatening diseases.Its patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic... 
Sector
Biotechnology & Medical Research
Calendar
02/08 | 08:30amPresentation
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
02/03 PLURISTEM THERAPEUTICS INC. : Pluristem's Placental Cells Prove Superior in Pre-..
01/28 PLURISTEM THERAPEUTICS : to Present at Bio CEO & Investor Conference in New York..
01/26 Pluristem to Present at Bio CEO & Investor Conference in New York City on Feb..
01/20 PLURISTEM THERAPEUTICS INC. : Pluristem to Commence Go-To-Market Pivotal Trial i..
01/13 PLURISTEM THERAPEUTICS : Receives U.S. FDA Clearance- to Initiate Clinical Trial..
01/13 PLURISTEM THERAPEUTICS : Receives U.S. FDA Clearance to Initiate Clinical Trial ..
01/12 Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 t..
01/06 New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Amelior..
More news
Sector news : Biotechnology & Medical Research - NEC
02/05 AMGEN : To Present At The Leerink Partners 5th Annual Global Healthcare Conferen..
02/05 SANOFI : Muzammil Mansuri is Sanofi’s new Executive Committee member
02/05 AMGEN : Positive topline results from GAUSS-3 trial of Repatha
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
02/03 Pluristem's Placental Cells Prove Superior In Pre-Eclampsia A Leading Cause O..
01/05 PREMARKET BIOTECH DIGEST : Exelixis Rallies, Shire-Baxalta Deal, Lipocine Commen..
01/04 PREMARKET BIOTECH DIGEST : Akebia In Focus, VIVUS's Positive Spin, Pershing's Va..
2015 Pluristem's PLX-PAD cells an Orphan Drug for preeclampsia
2015 PREMARKET GAINERS / LOSERS AS OF 9 : 15 am


Comments 
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Technical analysis trends PLURISTEM THERAPE...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions